Pemphigus is a chronic, muco-cutaneous autoimmune blistering disorder; two main variants being pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype, varying between 75 to 92% of total pemphigus patients. Although no community based studies are undertaken…
By Jay Glaser, M.D. Dr. Glaser is a board-certified internist, researcher and medical director at the Lancaster Ayurveda Medical Centers based in Sterling, MA. He can be reached at 978-422-5044. Answers to many questions about Ayurveda can be found on…
By Peggy Clinton, BSN, Eric Hill, Wanda Rogers, RPH As many of you know, Pemphigus is an immune-mediated blistering skin disease involving the IgG autoantibodies which bind to the cell wall of the epidermis. The specific pathway of the blistering…
by Christopher D. Saudek, M.D., Professor of Medicine, Johns Hopkins University School of Medicine, President, American Diabetes Association (July 2001). Steroids are commonly used in medicine, and their effects on blood sugar are often seriously underestimated. To give the bottom…
By Sergei A. Grando, M.D., Ph.D., D.Sci. Professor of Dermatology University of California Davis NPF Advisory Board Member The goal of my research is to develop a safer and more rational treatment for pemphigus. I am deeply concerned that we,…
By Grant J. Anhalt, M.D. and Hossein Nousari, M.D.Johns Hopkins University, School of Medicine In February 1997, the FDA approved a new drug, mycophenolate mofetil (MFM, also known as Cellcept) with an approved indication for use in immunosuppression of patients…
Grant J. Anhalt, MD Head, Dermatoimmunology Department Johns Hopkins University Baltimore, Maryland Vice President in charge of Scientific Affairs, The International Pemphigus Foundation
Prior to the introduction of an effective therapy with oral corticosteroids in the 1950s, the disease had a dismal natural course with a 50% mortality rate at 2 years and 100%
